Alnylam combines an unusually strong quality profile — wide economic moat, Rule of 40 score of 101, 96% year-over-year revenue growth, and a Piotroski financial health score of 8 out of 9 — with a forward earnings multiple that remains undemanding for growth of this caliber at a PEG of 0.49; the principal near-term obstacle is a confirmed technical downtrend that, until resolved, limits the initial position size for all but the most patient investors.
Thesis pillars
- Wide Moat Elite Growth Quality→Stable
- Confirmed Downtrend Blocks Entry→Stable
- Leverage Adds Downside Cushion Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Biotechnology
Wait for pullback to $303.91. Recent C-suite change — blocks BUY_NOW at $313.06. Engine's entry $303.91 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Leverage penalty (D/E 2.8): -1.5; Overbought (RSI 77).
Alnylam Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics; its six approved products include AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO (sold directly) plus Leqvio and Qfitlia (commercialized by Novartis and Sanofi). The company recognized $2.99... Read more
Wait for pullback to $303.91. Recent C-suite change — blocks BUY_NOW at $313.06. Engine's entry $303.91 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Leverage penalty (D/E 2.8): -1.5; Overbought (RSI 77). Chart setup: Death cross but MACD improving, RSI 77. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.54, quality 8.1/10, growth 10.0/10). Score 6.6/10, moderate confidence.
Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, positive momentum, news events none recent, earnings proximity 24d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Alnylam Pharmaceuticals, Inc.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals generated $2.99 billion in net product revenues in 2025 from four directly commercialized RNAi medicines — AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO — marking the company's first profitable fiscal year. AMVUTTRA received FDA approval for ATTR cardiomyopathy in March 2025, expanding its U.S. indication, with European Commission approval following in June 2025. Two additional products, Leqvio and Qfitlia, are commercialized by Novartis and Sanofi in markets now covering 108 countries for Leqvio.
Alnylam earns revenue from direct product sales through specialty distribution channels plus royalties and collaboration payments from Novartis (Leqvio), Sanofi (Qfitlia), Roche (zilebesiran), and Regeneron (cemdisiran). AMVUTTRA targets transthyretin protein synthesis via quarterly subcutaneous injection; coverage policies from Medicare, Medicaid, and private payors govern net realized pricing. The company relies on third-party contract manufacturers for commercial supply. The clinical pipeline adds potential upside: nucresiran entered Phase 3 trials TRITON-PN and TRITON-CM in 2025; zilebesiran entered the ZENITH Phase 3 cardiovascular outcomes trial in September 2025 alongside Roche; mivelsiran reported Phase 1 data in early-onset Alzheimer's disease in July 2025. Regeneron plans a U.S. regulatory submission for cemdisiran in generalized myasthenia gravis in the first quarter of 2026.
Show full overview
Pricing pressure from the Inflation Reduction Act could weigh on future AMVUTTRA revenues as the U.S. government expands its list of drugs subject to Medicare price negotiation. The 10-K explicitly identifies 'most-favored nation pricing measures, measures requiring the U.S. government in the future to negotiate the prices of certain drugs' as risks affecting AMVUTTRA commercialization. ATTR cardiomyopathy is a prevalent adult condition with a large Medicare patient population, and Alnylam's stated dependence on AMVUTTRA as a 'significant portion' of net product revenues places a defined ceiling risk on the TTR franchise's long-term net pricing.
See also: Healthcare · Biotechnology
From Alnylam Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-07Recent Developments — Alnylam Pharmaceuticals, Inc.
Latest news
- NEWS Alnylam (ALNY) Q1 earnings preview: What you should know beyond the headline estimates - MSN — MSN neutral
- NEWS Alnylam (ALNY) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance — Yahoo Finance neutral
- NEWS ALNY Earnings Preview: Alnylam Q1 2026 on April 30 - Meyka — Meyka neutral
- NEWS Alnylam Shareholders Reaffirm Board, Pay Practices and Auditor - TipRanks — TipRanks neutral
- NEWS RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $445 - Moomoo — Moomoo positive
Generated 2026-07-07T09:31:41Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductAMVUTTRA10-K Item 1A: 'a significant portion of our net product revenues was derived from the sale of our TTR products, and in particular AMVUTTRA'
Material Events(8-K, last 90d)
- 2026-05-27Item 5.02LOWBenjamin F. Cravatt, Ph.D. elected to the Board as Class III director effective June 1, 2026, filling a newly created vacancy; term expires at 2028 annual meeting. Annual cash retainer $75,000 plus stock options. Routine board expansion; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $303.91. Recent C-suite change — blocks BUY_NOW at $313.06. Engine's entry $303.91 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Leverage penalty (D/E 2.8): -1.5; Overbought (RSI 77). Chart setup: Death cross but MACD improving, RSI 77. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.54, quality 8.1/10, growth 10.0/10). Target $391.25 (+25.0%), stop $283.63 (−10.4%), A.R:R 2.0:1. Score 6.6/10, moderate confidence.
Take-profit target: $391.25 (+29.2% upside). Target $391.25 (+25.0%), stop $283.63 (−10.4%), A.R:R 2.0:1. Stop-loss: $283.63.
Leverage penalty (D/E 2.8): -1.5; Overbought (RSI 77); Below 200-MA, MA slope -6.0%/30d (confirmed downtrend).
Alnylam Pharmaceuticals, Inc. trades at a P/E of 78.8 (forward 23.0). TrendMatrix value score: 5.5/10. Verdict: Buy (Wait for Entry).
37 analysts cover ALNY with a consensus score of 3.9/5. Average price target: $435.
What does Alnylam Pharmaceuticals, Inc. do?Alnylam Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics; its six approved products...
Alnylam Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics; its six approved products include AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO (sold directly) plus Leqvio and Qfitlia (commercialized by Novartis and Sanofi). The company recognized $2.99 billion in net product revenues in 2025, its first profitable fiscal year, with AMVUTTRA as the dominant revenue driver following its FDA approval for ATTR cardiomyopathy in March 2025.